MarginsXMarginsX
Home › Markets › Health Care › TRIB

Trinity Biotech plc (TRIB)

TRIB trades on Nasdaq in Health Care, Biotechnology: In Vitro & In Vivo Diagnostic Substances. Numbers below come from the Nasdaq screener and SEC filings, each with its source.

Price · November 16, 2026
$5.38
-11.89% on the day
Market cap
$4.4M
Nano cap
Revenue · 2025
$43.8M
-28.9% on 2024
Net income · 2025
-$37.4M
-85.4% net margin

Price, change, market cap, sector and industry: Nasdaq stock screener, as of November 16, 2026. Revenue: SEC filing XBRL, 20-F (ifrs-full:Revenue), fiscal year ended 2025-12-31, https://www.sec.gov/Archives/edgar/data/888721/000155485526000848/0001554855-26-000848-index.htm. Net income: SEC 20-F (ifrs-full:ProfitLossAttributableToOwnersOfParent), fiscal year ended 2025-12-31.

Profile

FieldValue
TickerTRIB on Nasdaq
SectorHealth Care
IndustryBiotechnology: In Vitro & In Vivo Diagnostic Substances
CountryIreland
IPO year1992
SEC CIK0000888721
SEC industry codeIn Vitro & In Vivo Diagnostic Substances
Incorporated inIreland

Financials · 2025

LineValue
Revenue$43.8M
Net income-$37.4M
Operating income-$15.8M
Net margin-85.4%
Operating margin-36.1%
Revenue growth-28.9%
Cash$5.1M
Total assets$105.2M
P/E (computed)Net income was not positive
P/S (computed)0.1×

Warning signs

Cash runway
10.4 months
$5.1M cash at December 31, 2025
Share count, 1 year
+4.2%
2024-12-31 to 2025-12-31 · +1127.5% over 3 years
Going-concern doubt
No
20-F filed April 30, 2026
Insider net buying, 12 months
$0
Through September 30, 2026
SignFindingSource
Going concernNo going-concern finding.20-F 2026-04-30
Cash and burn$5.1M cash; operating cash flow -$1.5M a quarter.Report 2025-12-31
Shares outstanding623,678 (2025-12-31); 17,959,674 a year earlier; 7,621,514 three years earlier. 3y figure adjusted for splits (1-for-5 overall); the newest SEC cover-page count is from 2025-12-31; shares issued since then are not in these figures.Cover page 2025-12-31
Reverse splits, 3 years2; latest 1-for-30 on 2026-07-24Source 2026-07-24
Shelf and offerings, 12 months2 S-3/F-3 shelf filings; 1 424B5 takedowns, 1 at the marketLatest 2026-06-12
Exchange deficiency notices, 12 monthsNoneNone on EDGAR
AuditorGrant Thornton, Dublin, IrelandPCAOB Form AP 2026-06-03
Late filings, 12 monthsNoneNone on EDGAR
Insider trades, 12 monthsBought $0, sold $0 on the open marketSEC Forms 3/4/5 data sets 2026-09-30

From SEC EDGAR submissions, EDGAR full-text search, SEC's Forms 3/4/5 data sets and PCAOB Form AP; computed November 16, 2026. Runway is cash divided by average quarterly operating cash burn. Dilution compares cover-page share counts, corrected for recorded splits.

Annual results

Fiscal yearRevenueNet incomeOp. cash flowCashTotal debtTTM revenueSource
FY 2025
2025-12-31
$43.8M-$37.4M-$5.9M$5.1M$210K$43.8M20-F 2026-04-30
FY 2024
2024-12-31
$61.6M-$31.8M-$4.2M$5.2M$210K$61.6M20-F 2025-05-16
FY 2023
2023-12-31
$56.8M-$24.0M-$11.6M$3.7M$210K$56.8M20-F 2025-05-16
FY 2022
2022-12-31
$62.5M-$41.0M-$921K$6.6M$210K$62.5M20-F 2025-05-16
FY 2021
2021-12-31
$81.1M$875K$13.2M$25.9M$83.3M$81.1M20-F 2024-04-30
FY 2020
2020-12-31
$102.0M-$6.4M$23.8M$27.3M$1.0M$102.0M20-F 2023-05-16
FY 2019
2019-12-31
$90.4M-$28.9M$5.4M$15.2M$1.0M$90.4M20-F 2022-05-02
FY 2018
2018-12-31
$97.0M-$22.1M$7.2M$30.3M$99.9M$97.0M20-F 2021-04-30

From SEC XBRL company facts (annual reports only: 20-F or 40-F). Quarters a filing gives only as year-to-date are computed as differences (Q4 is the fiscal year minus nine months).

Key SEC documents

DocumentFormFiled
Latest prospectus or offering documentPOS AM2026-08-28
Latest annual report20-F2026-04-30
Latest quarterly / interim6-K2026-11-12

Source: SEC EDGAR submissions feed, 502 recent filings. All filings on EDGAR.

Price moves

WindowReturn
1 week+7.0%
1 month-3.2%
3 months-48.6%
Year to date-74.3%
1 year-76.1%
From 52-week high-84.1%

Source: Yahoo Finance daily closes, last bar 2026-11-13. Computed by MarginsX from daily closes; cap, sector and tier from the Nasdaq screener.

Peers in Biotechnology: In Vitro & In Vivo Diagnostic Substances

TickerCompanyPriceDayMarket cap
CDIOCardio Diagnostics Holdings Inc.$1.79-7.26%$5.3M
BMRABiomerica Inc.$1.32-2.94%$6.1M
VNRXVolitionRX Limited$0.1998-13.13%$7.2M
QCLSQ/C Technologies Inc.$0.3210+4.80%$2.6M
VRAXVirax Biolabs Group Limited$0.4480-26.87%$603K
IMDXInsight Molecular Diagnostics Inc.$1.86-13.08%$60.9M
ICCCImmuCell Corporation$11.42+6.23%$103.8M
TKNOAlpha Teknova Inc.$7.77-5.36%$488.8M

The full dossier has every filing, three years of financials, private raises and the people who signed them.

Open the full dossier